On Thursday, the U.S. Food and Drug Administration (FDA) lifted a long-standing requirement that physicians must distribute the abortion pill mifepristone to patients in person, but left in place several burdensome restrictions that continue to unnecessarily restrict and stigmatize this safe medication, say advocates. The decision came in response to a case filed by the ACLU on behalf of abortion providers and medical groups.

“It’s purely political. These pills should not only be in pharmacies, they should be available over-the-counter. But instead, years later, we’re still in a place where people think of this as a drug that is so dangerous it has to be in a black box.”